The Relative Densisties of Pharmaceutical Powders, Blends, Dry Granulations, and Immediate-Release Tablets

Hancock,Bruno;

The Relative Densisties of Pharmaceutical Powders, Blends, Dry Granulations, and Immediate-Release Tablets

April 2, 2003

By Bruno C. Hancock

News

Article

Pharmaceutical TechnologyPharmaceutical Technology-04-02-2003

Volume 27

Issue 4

The authors provide a combined source of density data and show that denity can be used as an equipment-independent sclaing parameter in the manufacture of common pharmaceutical solids.

External Link - article-52997.pdf

Articles in this issue

Outsourcing Outlook

April 2003

Identification of Out-of-Trend Stability Results

The Relative Densisties of Pharmaceutical Powders, Blends, Dry Granulations, and Immediate-Release Tablets

Overhauling Compliance and GMPs

A Film Approach for the Stabilization of Gelatin Preparations Against Cross-Linking

Related Content

Feb 2, 2020 South San Francisco / CA / USA - Genentech headquarters in Silicon Valley; Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009 | Image Credit: © Sundry Photography - stock.adobe.com

Genentech and Roche Expand US Footprint with New North Carolina Manufacturing Facility

Patrick Lavery

May 13th 2025

Article

The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas

June 25th 2024

Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

A laboratory technician performing a quality control test on a batch of pharmaceutical tablets, highlighting the importance of ensuring drug safety. | Image Credit: ©MAY -stock.adobe.com

Poor API Quality Threatens a Healthy Supply

Susan Haigney

May 9th 2025

Article

Poor API quality may often lead to delays in production and a shortage of supply.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

April 30th 2024

Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Image Credit: © Alessandro Grandini - stock.adobe.com

Understanding the Variability in Bioburden Test Results in Biomanufacturing

Naveenganesh Muralidharan

May 7th 2025

Article

This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.